drugset / Trial / NCT02418845

A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis

NCT02418845

Phase 3 Completed 189 enrolled Symbiomix Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this clinical trial is to test the safety and efficacy of the oral investigational new drug, SYM-1219 for the treatment of bacterial vaginosis.

Timeline

Start
2015-05-28
Primary completion
2015-10-05
Completion
2015-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Secnidazole Small molecule 2 g Oral

Indications